ProCE Banner Activity

Selecting First-line and Second-line Therapy in the Setting of EGFR Mutation–Positive NSCLC

Slideset Download
In this downloadable slideset, Edward S. Kim, MD, FACP, and H. Jack West, MD, review the latest first-line and second-line clinical data in the setting of EGFR mutation–positive NSCLC.

Released: March 02, 2018

Expiration: March 01, 2019

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Edward S. Kim

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas